[Ip-health] Act Up-Paris letter to EP Committee on Development about ACTA

Pauline Londeix pauline.londeix at gmail.com
Mon Jan 23 10:26:12 PST 2012


Début du message réexpédié :

> De : Pauline Londeix <pauline.londeix at gmail.com>
> Date : 23 janvier 2012 19:24:12 HNEC
> À : thijs.berman at europarl.europa.eu, michael.cashman at europarl.europa.eu, ricardo.corteslastra at europarl.europa.eu, corina.cretu at europarl.europa.eu, veronique.dekeyser at europarl.europa.eu, nirj.deva at europarl.europa.eu, leonidas.donskis at europarl.europa.eu, charles.goerens at europarl.europa.eu, cgreze at lesverts.fr, catherine.greze at europarl.europa.eu, eva.joly at europarl.europa.eu, filip.kaczmarek at europarl.europa.eu, michaltomasz.kaminski at europarl.europa.eu, franziska.keller at europarl.europa.eu, miguelangel.martinez at europarl.europa.eu, gay.mitchell at europarl.europa.eu, norbert.neuser at europarl.europa.eu, bill.newtondunn at europarl.europa.eu, maurice.ponga at europarl.europa.eu, jean.roatta at europarl.europa.eu, jroatta at assemblee-nationale.fr, birgit.schnieber-jastram at europarl.europa.eu, daniel.vanderstoep at europarl.europa.eu, michele.striffler at europarl.europa.eu, alf.svensson at europarl.europa.eu, eleni.theocharous at europarl.europa.eu, patrice.tirolien at europarl.europa.eu, ivo.vajgl at europarl.europa.eu, frank.vanhecke at europarl.europa.eu, anna.zaborska at europarl.europa.eu, iva.zanicchi at europarl.europa.eu, gabriele.zimmer at europarl.europa.eu
> Objet : Concerns regarding the Committee on development report on the ACTA
> 
> 
> Subject : Concerns regarding the Committee on development report on the ACTA
> 
>                                                                                                                         January 23, 2012
> 
> 
> Dear Member of the European Parliament,
> 
> We are writing to express our serious concerns about the draft opinion issued by the Committee on Development (DEVE) regarding the proposal for a Council decision on the Anti-Counterfeiting Trade Agreement (ACTA) and the lack of consultations with the civil society and patient groups by DEVE.
> 
> As an organization of people living with HIV that has been working for more than twenty years in the area of access to medicines , Act Up-Paris would like to attract your attention on the fact that, the present text, if ratified, will have serious consequences on the ability of people to access life-saving medicines. Indeed, as a result, ACTA will not only impact poor countries, where people continue to die because of the inaccessibility of essential medicines. This agreement will also have consequences in European countries, where the escalating price of drugs will, in the future, limit access to treatment and care for many people.
> 
> The report DEVE issued recently fails to notice the dramatic impact that ACTA will have on the public health both in the developing and in the developed countries. The commitments made by the European countries and the E.C to expand access to treatment and to ensure the universal access to AIDS, tuberculosis and malaria drugs, will never be reachable in light of such unbalanced provisions being part of an agreement signed by Europe. At the time of global financial crisis, it is nonsense to make drugs more expensive by such agreements thereby keeping them out of reach for many of us. The international organizations that fund medicines, such as the Global Fund against the three major pandemics, has already stopped providing treatment for people in need because of its lack of funding.
> 
> Indeed, within ACTA, among others, the following provisions may have a dramatic impact on the supplying of affordable medicines: i) The amalgamation between “trademark infringement”, “patent infringement” with counterfeits, which is leading to a confusion and provides a basis for seizures of legitimate generic medicines in transit (a new shipment of generic medicines was, once again, seized at EU customs last November), ii) imposing third party liability is  threatening the ability of suppliers to manufacture generics. 
> 
> As said above, we are very concerned about the process: has any single hearing been organized by DEVE to seek feedback from patient groups and treatment providers that had led you to the conclusion that the ACTA will not affect access to medicines? We believe that such report should not be considered as genuine without taking the inputs from such groups.
> 
> Act Up-Paris, by this letter, would formally like to urge you to organize a consultation with health experts and people living with the diseases as soon as possible to take their feedback and the likely impact on them of agreements like ACTA in terms of access to medicines.  
> 
> Yours sincerely,
> 
> Pauline Londeix
> Act Up-Paris 
> www.actupparis.org
> 
> 
> 



More information about the Ip-health mailing list